Breast Cancer
Conference Coverage
Tucatinib improves PFS, OS in HER2+ breast cancer with brain metastases
Conference Coverage
TRAIN-2: Anthracyclines added toxicity, with no increased efficacy, in HER2+ breast cancer
Conference Coverage
Capecitabine maintenance improved DFS, not OS, in TNBC patients
The 5-year disease-free survival rate was 83% in the capecitabine arm and 73% in the observation arm.
Conference Coverage
PPI added to chemo improves breast tumor response rate
Conference Coverage
Pembrolizumab plus chemo shows benefits for PD-L1–rich triple-negative breast cancer
Patients with triple-negative breast cancers with PD-L1 combined positive score higher than 10 had better progression-free survival with...
Conference Coverage
Active cancer increases death risk in patients with COVID-19
Conference Coverage
LOTUS: Ipatasertib plus paclitaxel may prolong OS in TNBC
Ipatasertib provided a “clinically meaningful,” but not statistically significant, 9-month improvement in median overall survival.
News
Patient-focused precautions, testing help blunt pandemic effects on heme-onc unit
Multiple factors helped keep the anticipated COVID-19 surge manageable at the hematologic oncology service of Levine Cancer Institute.
News
Oncologists’ income and satisfaction are up
News
Tumor molecular profiling may help identify ‘exceptional responders’